However, in patients undergoing renal replacement therapy (either hemodialysis or continuous peritoneal dialysis), irrespective of the presence of diabetes mellitus, the serum levels of inflammatory markers (i.e., IL-6, IL beta, IL 10, or TNF alpha) are heterogenous [14,15,16]. The gene discussed is IL6; the disease is diabetes mellitus.